Efficacy and Safety of Apatinib in Treating Advanced Colorectal Cancer

• Published in: Zhōngguó yīxué kēxuéyuàn xuébào Vol. 41; no. 2; p. 170
• Main Authors: Li, Ning Ning, Zhou, Jian Feng, Zhao, Lin, Ying, Hong Yan, Jia, Ning
• Format: Journal Article
• Language: Chinese
• Published: China 28.04.2019
• Subjects: Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Colorectal Neoplasms - drug therapy; Humans; Pyridines - adverse effects; Pyridines - therapeutic use; Retrospective Studies; Survival Analysis
• ISSN: 1000-503X
• DOI: 10.3881/j.issn.1000-503X.10376

Objective To assess the efficacy and safety of apatinib in the treatment of advanced colorectal cancer(CRC). Methods The clinical data of 16 CRC patients treated with apatinib after failure of prior lines of treatment were retrospectively analyzed in terms of objective response rate,disease control rate,progression-free survival,overall survival,adverse events,and prognostic factors. Results The efficacy was evaluable in 14 patients,among whom the objective response rate was 7.1% and the disease control rate was 50%.The median progression-free survival was 3 months(95%CI=1.57-4.42),and the median overall survival was 6.5 months(95%CI=4.10-8.89).The safety was evaluable in 16 patients,among whom the most common grade 3 adverse events were hypertensinon(37.5%)and proteinuria(25%).No grade 4 adverse event was observed.Multivariate analysis did not show any factor directly related to survival. Apatinib may be effective in treating advanced CRC,with tolerable side effects.